Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Apr:222:112070.
doi: 10.1016/j.diabres.2025.112070. Epub 2025 Feb 26.

Transitioning between automated insulin delivery systems: A focus on personalisation

Pilar Isabel Beato-Víbora  1 , Ana Chico  2 , Jesus Moreno-Fernandez  3 , Sharona Azriel-Mira  4 , Lia Nattero-Chávez  5 , Rosario Vallejo Mora  6 , Núria Alonso-Carril  7 , Olga Simó-Servat  8 , Eva Aguilera-Hurtado  9 , Luz María Reyes Céspedes  10 , Marisol Ruiz de Adana  11 , Marta Domínguez  12 , Rosa Márquez-Pardo  13 , Gonzalo Díaz-Soto  14 , María Asunción Martínez-Brocca  15 , Khusama Alkadi Fernández  16 , Macarena Alpañés Buesa  17 , Martín Cuesta Hernández  18 , Carmen Quirós  7
Affiliations
Multicenter Study

Transitioning between automated insulin delivery systems: A focus on personalisation

Pilar Isabel Beato-Víbora et al. Diabetes Res Clin Pract. 2025 Apr.

Abstract

Background: Automated insulin delivery (AID) systems are the most effective treatment for type 1 diabetes (T1D). When targets are not achieved, transitioning between AID systems is an option. The aim was to assess the impact of switching between systems on glucose control and user satisfaction.

Methods: A multicenter, cross-sectional analysis was conducted. T1D subjects who had switched between AID systems were included. Glycaemic control was compared before the switch, after 14 days, and after 3 months of use of the new system. The participants completed a satisfaction survey.

Results: 96 subjects were included (age: 40.8 ± 11.5 years, 73 % female, HbA1c: 6.94 ± 0.68 % (52.3 ± 7 mmol/mol)). The AID systems evaluated included MiniMedTM-780G, Diabeloop-DBLG1, Tandem-t:slim-x2TM-Control-IQTM, and CamAPS-FX. GMI improved from 6.92 ± 0.49 % to 6.71 ± 0.37 % after 14 days and to 6.68 ± 0.36 % after 3 months and Time in Range 70-180 mg/dl increased from 70.53 ± 11.43 % to 75.73 ± 8.33 % after 14 days and to 75.65 ± 7.64 % after 3 months (p < 0.001 to baseline). The majority of the participants reported higher satisfaction. The factors that most affected satisfaction were the size of the system, the performance of the sensor, and the specificities of the control algorithm.

Conclusion: Transitioning between AID systems can enhance glucose control and user satisfaction without compromising glycaemic stability during the adjustment period.

Keywords: Automated insulin delivery system; Closed-loop systems; Pregnancy; Time in range; Type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: PB has received speaking/consulting honoraria from Abbott, Novo Nordisk, Medtronic, Roche, Novalab, Ypsopmed, and Lilly; JMF has received speaking/consulting honoraria from Abbott, Dexcom, Medtronic, Roche, Novalab and Ypsomed; JM has received speaking/consulting honoraria from Abbott, Dexcom, Medtronic, Roche, Novalab and Ypsomed; AC has received grants to attend conferences from Roche, Lilly, MSD, Esteve, Sanofi, Novalab, Novo Nordisk, Dexcom, has formed part of Advisory Boards of Abbott, Lilly, Novo Nordisk, Sanofi, Air Liquide, Ypsomed, and has received support for the development of material, clinical trials, courses, etc. from Roche, Novo Nordisk, Abbott, Dexcom. SA has received grants to attend conferences fromAbbott, Amgen, Astrazeneca, Boehringer, Dexcom, Lilly, Lundbeck, Medtronic, Mundipharma, Novartis, NovoNordisk, Roche, Sanofi, Ypsomed and has formed part of Advisory Boards of Abbott, Novo Nordisk, Sanofi; LN has received speaking/consulting honoraria from Abbott, Novo Nordisk, Medtronic, Roche, Dexcom, Novalab and Sanofi; RV has received speaking/consulting honoraria from Abbott, Novo Nordisk, Roche and Lilly; NA has received speaking/consulting honoraria from Medtronic, Novo Nordisk and Lilly; OS has received speaking honoraria from Dexcom, Medtronic, Novo Nordisk, Lilly, Novalab; EA has received grants to attend conferences from Sanofi, NovoNordisk, Medtronic, speaking/consulting honorariafromSanofi, Abbott, Novo Nordisk, Dexcom, Medtronic and support for the development of material, clinical trials, courses, etc. from Novo Nordisk, Abbott, Lilly, Sanofi; LR has received speaking/consulting honoraria from Novo Nordisk and Dexcom; MR has received grants to attend conferences from Roche, Lilly, MSD, Esteve, Sanofi, Novalab, Novo Nordisk, Dexcom and Medtronic and support for the development of material, clinical trials, courses, etc. from Roche, Novo Nordisk, Abbott, Dexcom; MD has no conflict of interest, RM has no conflict of interest; GD has received grants to attend conferences from Lilly, Abbott, Medtronic and Novo Nordisk and formed part of Advisory Boards of Abbott, Lilly, Novo Nordisk, and Medtronic; MM has received consulting honoraria from Sanofi and research grants from Abbott and Ascensia; KA received grants to attend conferences and courses from Medtronic, Ypsomed, Novo Nordisk, Abbott, Lilly, Novalab, Air Liquide, Dexcom; MA has no conflict of interest; MC has received speaking/consulting honoraria from Abbott, Dexcom, Novo Nordisk, Medtronic, Roche, Novalab, Sanofi and Lilly; CQ has received speaking/consulting honoraria from Medtronic, and Air Liquide.

Publication types

MeSH terms